Core Viewpoint - Jinbo Biological, known as the "first stock of recombinant collagen," has seen its stock price surge significantly, reaching a new high of 577.5 yuan, with a cumulative increase of 140% over two months, reflecting strong market sentiment and investor interest in the North Exchange [2][6]. Company Performance - Jinbo Biological's stock price rose from 240 yuan in early March to 577.5 yuan by May 21, 2025, marking a 140% increase [6]. - The company reported a revenue of 1.443 billion yuan for 2024, a year-on-year increase of 84.92%, and a net profit of 732 million yuan, up 144.3% [6]. - In Q1 2025, Jinbo achieved a revenue of 366 million yuan, a 62.51% increase year-on-year, with a net profit of 169 million yuan, reflecting a 66.25% growth [6]. Market Dynamics - The North Exchange market has been buoyed by Jinbo Biological's performance, contributing to the North 50 Index reaching historical highs [5][9]. - The North Exchange has seen a significant increase in market activity, with nearly 90% of stocks rising and several stocks experiencing over 10% gains [4][5]. Regulatory Environment - The China Securities Regulatory Commission (CSRC) has expressed strong support for the reform of the North Exchange, aiming to enhance its role in serving innovative small and medium-sized enterprises [5][9]. - Recent regulatory changes have introduced mechanisms for expedited reviews of mergers and acquisitions, aimed at optimizing resource allocation and supporting high-quality development [10]. Future Outlook - Analysts believe that the North Exchange has further upward potential, with strong performance from quality stocks and ongoing market interest [11]. - Jinbo Biological plans to maintain its focus on innovation and core business development, aiming to enhance shareholder value and improve communication with investors [8].
错过一个亿！“胶原蛋白茅”股价大涨140％至577元疯狂出圈，北证50再创新高